Solventum said it is acquiring Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care.
The deal is for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones.
Founded in 2013, Acera has developed and commercialized synthetic treatment options for soft tissue repair, leveraging a proprietary electrospinning technology platform. The company's Restrata products are currently available in the U.S. and used to treat hard-to-heal, complex wounds in acute care settings.
The combination is expected to enable accelerated adoption of Restrata products in the acute care market and generate synergies by leveraging Solventum's global footprint, specialized wound care sales force, and leadership in negative pressure wound therapy.
"Regenerative wound care is an exciting and fast-growing space, and Acera has innovative technology to meet a significant unmet need in acute wound care," said Bryan Hanson, chief executive officer of Solventum. "Expanding our advanced wound care portfolio into the high-growth synthetic tissue matrices category complements solutions within our existing portfolio and enhances the options our specialized commercial team can provide doctors, nurses, and decision makers within acute care settings.
Acera is expected to generate approximately $90 million in sales in 2025.
Solventum plans to use its cash on hand to finance the transaction, with no additional debt or use of its credit line, and expects to complete the transaction in the first half of 2026, subject to customary closing conditions.
